ENDRA Life Sciences Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ENDRA Life Sciences Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | Mar 25, 2021 |
| FY2020 | Dec 31, 2019 | $0 | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $6.2K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $351.6K | Mar 11, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $351.6K | Mar 20, 2018 |
| FY2017 | Dec 31, 2016 | $515.6K | Mar 20, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | Mar 25, 2021 |
| FY2020 | Dec 31, 2019 | $0 | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $6.2K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $178.8K | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $279.7K | Mar 20, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.03M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($11.51M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($10.06M) | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | ($13.18M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($11.23M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($11.73M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($13.31M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($9.80M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($5.38M) | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | ($2.78M) | Mar 20, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.76M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($10.82M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($10.52M) | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | ($13.16M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($11.50M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($11.50M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($10.84M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($9.02M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($4.63M) | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | ($1.79M) | Mar 20, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.85M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.19M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.00M | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | $6.55M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $5.48M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $5.92M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $6.57M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $4.72M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $1.93M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $495.4K | Mar 20, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.18M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($7.40M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($9.55M) | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | ($12.77M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($11.12M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($10.75M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($8.59M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($7.70M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($3.30M) | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | ($1.32M) | Mar 20, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.3K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $16.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $33.9K | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | $202.6K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $45.0K | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $75.3K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $43.6K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $100.0K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $7.9K | Mar 11, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.85M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.45M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $6.75M | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | $9.27M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $12.87M | Mar 16, 2023 |
| FY2020 | Dec 31, 2020 | $8.76M | Mar 25, 2021 |
| FY2020 | Dec 31, 2019 | $7.18M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $7.22M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $6.12M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $490.8K | Mar 20, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.59M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.89M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.10M | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | $2.07M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $2.09M | Mar 16, 2023 |
| FY2020 | Dec 31, 2020 | $1.60M | Mar 25, 2021 |
| FY2020 | Dec 31, 2019 | $2.42M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $974.6K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $848.2K | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $1.38M | Mar 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.26M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.56M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $5.66M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $7.20M | Apr 7, 2025 |
| FY2023 | Dec 31, 2021 | $10.78M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $7.17M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $4.76M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $6.25M | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $5.28M | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | ($893.8K) | Mar 11, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($110.47M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($103.44M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($91.93M) | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | ($81.87M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($68.69M) | Mar 16, 2023 |
| FY2020 | Dec 31, 2020 | ($57.34M) | Mar 25, 2021 |
| FY2020 | Dec 31, 2019 | ($45.22M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($27.69M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($17.90M) | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | ($12.52M) | Mar 20, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Apr 7, 2025 |
| FY2024 | Dec 31, 2023 | $0 | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $546.6K | Mar 16, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (8) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (56) | Mar 31, 2026 |
| FY2022 | Dec 31, 2022 | (4) | Mar 16, 2023 |
| FY2022 | Dec 31, 2021 | (5) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 30, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (8) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (56) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (2,766) | Apr 7, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.18M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 536,908 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 5,937 | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | 3.17M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 2.13M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 34.05M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 8.42M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 7.42M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | 3.92M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | 723,335 | Mar 20, 2018 |